Angiodynamic opened at $12.42, in line with its previous close of $12.42. In the last trading session, the stock traded between $11.98 and $12.47. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Angiodynamic is now worth
$ 40.54
Resulting in a loss of
$ 59.46 (59.46%)
Note: Past profits do not guarantee future returns.
Rating from 2 Analysts
Today's Change
$-0.44 (-3.50%)
Day High
$12.47
Day Low
$11.98
Day Open
$12.42
Prev Close
$12.42
Volume
2,42,751
1W Return
-2.10%
1M Return
4.93%
3M Return
-23.86%
6M Return
10.56%
1Y Return
-4.96%
Market Cap ($ Mn)
504
PE Ratio
-
PB Ratio
3.87
PEG Ratio
-
ROE
-17.75%
ROCE
-16.55%
EPS (TTM)
$-0.17
1 Week
-2.10%
1 Month
4.93%
3 Months
-23.86%
6 Months
10.56%
9 Months
5.41%
AngioDynamics grants inducement awards to new CEO Eric Honroth
AngioDynamics granted 164,121 shares in inducement awards to new CEO Eric Honroth. Awards include time-based and performance-based RSUs under Nasdaq Rule 5635(c)(4). Performance-based tranche ties vesting to revenue, adjusted EBITDA, and relative TSR. Total share count splits into three awards with varying vesting schedules from 2 to 4 years.
6 days agoHC Wainwright maintains Buy on AngioDynamics, cuts target to $18
HC Wainwright maintains a Buy rating on AngioDynamics. Price target lowered from $19 to $18. Analyst Yi Chen issued the rating and target update.
1mo agoAngioDynamics Q1FY27 Results: Adjusted EPS beats estimate, sales rise 6.9%
Net sales rose 6.9% YoY to $80.9 million, beating consensus estimates. Adjusted loss per share narrowed to $(0.04), significantly beating the $(0.11) estimate. Med Tech segment revenue expanded 13.2% to $39.9 million, driving overall growth. FY2027 guidance affirmed: Revenue $336.0M-$341.0M and Adj EPS $(0.29)-$(0.24). Gross margin improved 410 bps to 59.4%, aided by tariff refunds and product mix.
1mo agoCanaccord Genuity raises AngioDynamics price target to $20
Canaccord Genuity analyst John Young maintained a Buy rating on AngioDynamics (NASDAQ: ANGO) and increased the price target to $20 from $16.
4mo agoAngioDynamics Reports Record Fiscal Year 2026 Results; FY2027 Sales Guidance Tops Estimates
AngioDynamics delivered record fiscal year 2026 results with pro forma net sales of $320.2 million (+9.4% YoY), driven by 18.4% Med Tech growth to $150.0 million and a seventh consecutive quarter of double-digit Med Tech expansion. The company ended the year with $53.9 million in cash and a debt-free balance sheet, and issued FY2027 net sales guidance of $336.0M–$341.0M, surpassing analyst consensus of $329.6 million.
4mo agoAngioDynamics to report fiscal 2026 Q4 and full-year results on July 14
AngioDynamics is set to report its fiscal 2026 fourth quarter and full-year financial results on July 14, 2026, prior to market open. A conference call to review the results will take place at 8:00 am ET, accessible via webcast or telephone.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $109.29 | -1.06% | $1,89,283.94M | 36.28 | |
| $449.53 | -0.11% | $1,55,826.88M | 42.73 | |
| $101.61 | +0.02% | $1,29,976.46M | 24.46 | |
| $318.79 | -1.70% | $1,21,360.48M | 34.27 | |
| $45.13 | +0.96% | $65,414.72M | 18.96 | |
| $105.81 | +1.73% | $60,840.75M | 53.70 | |
| $214.52 | +0.90% | $58,432.46M | 44.07 | |
| $82.60 | -1.26% | $37,346.60M | 16.49 | |
| $42.16 | +3.06% | $37,044.18M | 89.05 | |
| $72.46 | -2.16% | $35,027.16M | 54.55 | |
| $237.20 | +1.61% | $33,458.08M | 23.04 | |
| $80.35 | +0.53% | $29,964.75M | 36.04 |
An investment of $100 made 5 years ago in Angiodynamic is now worth
$ 40.54
Resulting in a loss of
$ 59.46 (59.46%)
Note: Past profits do not guarantee future returns.
